Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

620P - Efficacy, safety and PKPD of 23ME-00610, a first-in-class anti-CD200R1 antibody, in patients with tumor mutational burden-high (TMB-H) and/or microsatellite instability-high (MSI-H) cancers: Results from an expansion cohort

Date

14 Sep 2024

Session

Poster session 01

Topics

Clinical Research;  Immunotherapy

Tumour Site

Presenters

Aung Naing

Citation

Annals of Oncology (2024) 35 (suppl_2): S482-S535. 10.1016/annonc/annonc1589

Authors

A. Naing1, A.R. Khaki2, S. Kummar3, M.N. Al-Hallak4, A.R. Abdul Razak5, A.N. Diep6, M. Schmidt6, D. Maslyar6, R. Vold6, C.C. Hwang6, D.M. Glatt6

Author affiliations

  • 1 Investigational Cancer Therapeutics, The University of Texas M. D. Anderson Cancer Center, 77030 - Houston/US
  • 2 Medicine Department, Stanford University, 94305 - Stanford/US
  • 3 Division Of Hematology & Medical Oncology, OHSU Knight Cancer Institute - Center for Health and Healing Building 1 - South Waterfront, 97239 - Portland/US
  • 4 Department Of Oncology, Karmanos Cancer Institute, 48201 - Detroit/US
  • 5 Department Of Medical Oncology, Princess Margaret Cancer Centre, M5G 2C4 - Toronto/CA
  • 6 Therapeutics Development, 23andMe, Inc, 94080 - South San Francisco/US

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 620P

Background

23ME-00610, an anti-CD200R1 antibody, is being evaluated in a Phase 1/2a clinical trial in patients with advanced solid malignancies (NCT05199272) and has demonstrated acceptable safety and tolerability, with favorable PK and peripheral CD200R1 saturation, and anti-tumor activity [1,2]. Here, we report data from the TMB/MSI-H Phase 2a expansion cohort for the first time.

Methods

Patients had histologically-diagnosed locally advanced or metastatic TMB/MSI-H solid cancers, including patients with TMB ≥ 10 and ≥ 20 mutations/mb. Patients received 1400 mg given IV every 3 weeks until disease progression, unacceptable toxicity, or withdrawal from study. Exploratory biomarkers included CD200/R1 tumor expression, host genotyping, and peripheral target engagement. Adverse events (AEs) were assessed using CTCAE v5. Disease assessments were conducted every 8 weeks, and response was assessed by investigators using RECIST 1.1 criteria.

Results

Between June 20, 2023 and February 28, 2024, 12 patients, median age 58.5 years (range 36-79), with locally advanced or metastatic TMB-H (N=8; 66.7%) and/or MSI-H (N=4; 33.3%) solid cancers who received a median of 5 prior treatments (range 3-11; prior immunotherapy in 75%) were enrolled. Patients received a median of 3 cycles of 23ME-00610 (range 1-7), with 4 patients remaining on study by the April 1, 2024 data cutoff. Related non-serious AEs occurred in 7 patients (58.3%), including 2 patients (16.7%) with G3 anaemia (N=1) and G3 lymphocyte decrease (N=1). One incident of non-related G2 dyspnea led to dose interruption. No study drug related AEs/immune related AEs (irAEs) ≥ G3, or events leading to 23ME-00610 discontinuation, were reported. In the 10 efficacy evaluable patients, stable disease rate was 40%. 1400 mg resulted in full peripheral saturation of CD200R1.

Conclusions

23ME-00610 continues to show acceptable safety and tolerability, full peripheral target engagement, and PK that supports Q3W dosing, though limited anti-tumor activity as monotherapy in a small cohort of participants with TMB-H/MSI-H tumors. 1. Rasco, et al. SITC 2023 2. Glatt, et al. SITC 2023.

Clinical trial identification

NCT05199272.

Editorial acknowledgement

Legal entity responsible for the study

23andMe, Inc.

Funding

23andMe, Inc.

Disclosure

A. Naing: Financial Interests, Personal, Advisory Board: CTI, Deka Biosciences, Janssen Biotech, NGM Bio, PsiOxus Therapeutics, Immune-Onc Therapeutics, STCube Pharmaceuticals, OncoSec Keynote 695, Genome & Company, CytomX Therapeutics, Nouscom, Merck Sharp & Dohme Crop, Servier, Lynx Health, AbbVie, PsiOxus; Financial Interests, Institutional, Invited Speaker: AKH Inc., ASCO Direct Oncology Highlights, European Society for Medical Oncology; Financial Interests, Personal, Invited Speaker: Lynx Group, Society for Immunotherapy of Cancer, Korean Society of Medical Oncology, Scripps Cancer Care Symposium, CME Outfitters; Financial Interests, Institutional, Coordinating PI: NCI, EMD Serono; Financial Interests, Personal, Local PI: MedImmune, Healios Onc. Nutrition, Atterocor/Millendo; Financial Interests, Institutional, Local PI: Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte, Novartis, Regeneron, Merck, Bristol Myers Squibb, Pfizer, CytomX Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance Biosciences, Eli Lilly, Kymab PsiOxus, Arcus Biosciences, NeoImmuneTech, Immune-Onc Therapeutics, Surface Oncology, Monopteros Therapeutics, BioNTech Se, Seven & Eight Biopharma, SOTIO Biotech AG; Other, Travel and Accommodation: ARMO BioSciences, NeoImmune Tech, NGM BioPharmaceuticals. A.R. Khaki: Financial Interests, Institutional, Local PI: 23andMe, Janssen, Acrivon Therapeutics; Non-Financial Interests, Advisory Role, Consulting/advisory, declined compensation: Janssen. S. Kummar: Financial Interests, Personal, Advisory Board: Bayer, Gilead, Mundibiopharma, Springworks Theraepeutics, HarbourBiomed, Oxford BioTherapeutics, BPGbio Therapeutics, XYOne Therapeutics, GI Innovation Inc.; Financial Interests, Personal, Advisory Board, Spouse: Cadila Pharmaceuticals; Financial Interests, Personal, Other, Chair, DSMC: Mirati; Financial Interests, Personal, Advisory Board, Consultant: Genome Insight; Financial Interests, Personal, Ownership Interest: Pahtomiq; Financial Interests, Personal, Ownership Interest, Spouse (co-founder): Arexeon; Financial Interests, Personal, Stocks/Shares: Fortress Biotech; Financial Interests, Personal, Other, co-founder: Pathomiq; Financial Interests, Institutional, Local PI, Trial funding: ADC Therapeutics, Pionyr Therapeutics, Eisai, Bristol Myers Squibb, Syndax, SeaGen, ORIC, EMD Serono, Genome & Company, Moderna, Amgen, ASTX Therapeutics, PMV Pharmaceuticals, Elevation Oncology, Gilead, Day One BioPharmaceuticals, Sillajen Inc.; Financial Interests, Institutional, Local PI, trial funding: 23&Me; Financial Interests, Institutional, Local PI, Trial Funding: Deciphera Pharmaceuticals Llc, AstraZeneca, Immunitas Therapeutics, Inc., Mirati Therapeutics Inc, Transcenta Therapeutics, Inc., Adanate, Inc, GV20 Therapeutics Llc, Blueprint Medicines Corp, Nuvectis Pharma, Inc., Fog Pharmaceuticals. M.N. Al-Hallak: Financial Interests, Personal, Invited Speaker: Ipsen, AstraZeneca, Guardant Health, Takeda, Seagen; Financial Interests, Research Grant: Purple Biotech, U CAN-CER VIVE Foundation; Financial Interests, Local PI: Purple Biotech, Amgen, Incyte Corporation, Merus, Mirror Biologics, Tvardi, Astellas, Roche, 23andMe, Inc, NuCana, Refmal; Financial Interests, Personal, Local PI, Invited Speaker: AstraZeneca. A.R. Abdul Razak: Financial Interests, Personal, Invited Speaker: Medison; Financial Interests, Institutional, Local PI: 23&Me, Abbisko, AbbVie, Adaptimmune, Amgen, AstraZeneca, Bayer, Biontech, Blueprint Medicine, Boehringer Ingelheim, Bristol Myers Squibb, Cogent Biosciences, Daiichi Sankyo, Deciphera, Frontier Biopharma, Gilead, GSK, Iterion Therapeutics, Karyopharm Therapeutics, MedImmune, Medison, Merck, Neoleukin, Novartis, Pfizer, Polaris, Roche/Genentech, Rain Therapeutics and Symphogen.; Non-Financial Interests, Advisory Role: Boehringer Ingelheim, Medison, Inhibrx. A.N. Diep: Financial Interests, Institutional, Full or part-time Employment: 23andMe, Inc.; Financial Interests, Institutional, Stocks/Shares: 23andMe, Inc. M. Schmidt: Financial Interests, Institutional, Full or part-time Employment: 23andMe; Financial Interests, Institutional, Stocks/Shares: 23andMe. D. Maslyar, R. Vold, C.C. Hwang: Financial Interests, Institutional, Full or part-time Employment: 23andMe. D.M. Glatt: Financial Interests, Institutional, Full or part-time Employment: 23andMe; Financial Interests, Institutional, Stocks/Shares: 23andMe.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.